GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice.
Gaucher disease
Lipid dyshomeostasis
Myelination
Neurodegeneration
Oligodendrocyte
Parkinson’s disease
White matter
β-glucocerebrosidase
Journal
Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
28
06
2023
accepted:
20
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
Mutations in the β-glucocerebrosidase (GBA1) gene do cause the lysosomal storage Gaucher disease (GD) and are among the most frequent genetic risk factors for Parkinson's disease (PD). So far, studies on both neuronopathic GD and PD primarily focused on neuronal manifestations, besides the evaluation of microglial and astrocyte implication. White matter alterations were described in the central nervous system of paediatric type 1 GD patients and were suggested to sustain or even play a role in the PD process, although the contribution of oligodendrocytes has been so far scarcely investigated. We exploited a system to study the induction of central myelination in vitro, consisting of Oli-neu cells treated with dibutyryl-cAMP, in order to evaluate the expression levels and function of β-glucocerebrosidase during oligodendrocyte differentiation. Conduritol-B-epoxide, a β-glucocerebrosidase irreversible inhibitor was used to dissect the impact of β-glucocerebrosidase inactivation in the process of myelination, lysosomal degradation and α-synuclein accumulation in vitro. Moreover, to study the role of β-glucocerebrosidase in the white matter in vivo, we developed a novel mouse transgenic line in which β-glucocerebrosidase function is abolished in myelinating glia, by crossing the Cnp1-cre mouse line with a line bearing loxP sequences flanking Gba1 exons 9-11, encoding for β-glucocerebrosidase catalytic domain. Immunofluorescence, western blot and lipidomic analyses were performed in brain samples from wild-type and knockout animals in order to assess the impact of genetic inactivation of β-glucocerebrosidase on myelination and on the onset of early neurodegenerative hallmarks, together with differentiation analysis in primary oligodendrocyte cultures. Here we show that β-glucocerebrosidase inactivation in oligodendrocytes induces lysosomal dysfunction and inhibits myelination in vitro. Moreover, oligodendrocyte-specific β-glucocerebrosidase loss-of-function was sufficient to induce in vivo demyelination and early neurodegenerative hallmarks, including axonal degeneration, α-synuclein accumulation and astrogliosis, together with brain lipid dyshomeostasis and functional impairment. Our study sheds light on the contribution of oligodendrocytes in GBA1-related diseases and supports the need for better characterizing oligodendrocytes as actors playing a role in neurodegenerative diseases, also pointing at them as potential novel targets to set a brake to disease progression.
Sections du résumé
BACKGROUND
BACKGROUND
Mutations in the β-glucocerebrosidase (GBA1) gene do cause the lysosomal storage Gaucher disease (GD) and are among the most frequent genetic risk factors for Parkinson's disease (PD). So far, studies on both neuronopathic GD and PD primarily focused on neuronal manifestations, besides the evaluation of microglial and astrocyte implication. White matter alterations were described in the central nervous system of paediatric type 1 GD patients and were suggested to sustain or even play a role in the PD process, although the contribution of oligodendrocytes has been so far scarcely investigated.
METHODS
METHODS
We exploited a system to study the induction of central myelination in vitro, consisting of Oli-neu cells treated with dibutyryl-cAMP, in order to evaluate the expression levels and function of β-glucocerebrosidase during oligodendrocyte differentiation. Conduritol-B-epoxide, a β-glucocerebrosidase irreversible inhibitor was used to dissect the impact of β-glucocerebrosidase inactivation in the process of myelination, lysosomal degradation and α-synuclein accumulation in vitro. Moreover, to study the role of β-glucocerebrosidase in the white matter in vivo, we developed a novel mouse transgenic line in which β-glucocerebrosidase function is abolished in myelinating glia, by crossing the Cnp1-cre mouse line with a line bearing loxP sequences flanking Gba1 exons 9-11, encoding for β-glucocerebrosidase catalytic domain. Immunofluorescence, western blot and lipidomic analyses were performed in brain samples from wild-type and knockout animals in order to assess the impact of genetic inactivation of β-glucocerebrosidase on myelination and on the onset of early neurodegenerative hallmarks, together with differentiation analysis in primary oligodendrocyte cultures.
RESULTS
RESULTS
Here we show that β-glucocerebrosidase inactivation in oligodendrocytes induces lysosomal dysfunction and inhibits myelination in vitro. Moreover, oligodendrocyte-specific β-glucocerebrosidase loss-of-function was sufficient to induce in vivo demyelination and early neurodegenerative hallmarks, including axonal degeneration, α-synuclein accumulation and astrogliosis, together with brain lipid dyshomeostasis and functional impairment.
CONCLUSIONS
CONCLUSIONS
Our study sheds light on the contribution of oligodendrocytes in GBA1-related diseases and supports the need for better characterizing oligodendrocytes as actors playing a role in neurodegenerative diseases, also pointing at them as potential novel targets to set a brake to disease progression.
Identifiants
pubmed: 38454456
doi: 10.1186/s13024-024-00713-z
pii: 10.1186/s13024-024-00713-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Subventions
Organisme : Department of Molecular Medicine, University of Pavia
ID : PRID-DMM
Organisme : STARS Grants programme, University of Padova
ID : WRAPS
Organisme : Ministero dell'Istruzione, dell'Università e della Ricerca
ID : P2022Y2A3L
Informations de copyright
© 2024. The Author(s).
Références
Stirnemann J, Belmatoug N, Camou F, Serratrice C, Froissart R, Caillaud C, et al. A Review of Gaucher Disease pathophysiology, clinical presentation and treatments. Int J Mol Sci. 2017;18:441.
doi: 10.3390/ijms18020441
Rosenbloom BE, Weinreb NJ. Gaucher Disease: a comprehensive review. Crit Rev Oncog [Internet]. 2013 [cited 2023 May 19];18. Available from: https://www.dl.begellhouse.com/journals/439f422d0783386a,0dc6d82859623d4b,3b64a9681182c9cf.html .
Dandana A, Ben Khelifa S, Chahed H, Miled A, Ferchichi S. Gaucher Disease: clinical, biological and therapeutic aspects. Pathobiology. 2015;83:13–23.
doi: 10.1159/000440865
Schiffmann R, Sevigny J, Rolfs A, Davies EH, Goker-Alpan O, Abdelwahab M, et al. The definition of neuronopathic Gaucher disease. J Inherit Metab Dis. 2020;43:1056–9.
doi: 10.1002/jimd.12235
Sidransky E. Gaucher Disease: insights from a rare mendelian disorder. Discov Med. 2012;14:273–81.
Orvisky E, Park J k, Parker A, Walker J m, Martin B m, Stubblefield B k, et al. The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease. Hum Mutat. 2002;19:458–9.
doi: 10.1002/humu.9024
Schueler UH, Kolter T, Kaneski CR, Blusztajn JK, Herkenham M, Sandhoff K, et al. Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: a model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis. 2003;14:595–601.
doi: 10.1016/j.nbd.2003.08.016
Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004;82:192–207.
doi: 10.1016/j.ymgme.2004.04.011
Farfel-Becker T, Vitner EB, Pressey SNR, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet. 2011;20:1375–86.
doi: 10.1093/hmg/ddr019
Farfel-Becker T, Vitner EB, Kelly SL, Bame JR, Duan J, Shinder V, et al. Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum Mol Genet. 2014;23:843–54.
doi: 10.1093/hmg/ddt468
Stoker TB, Torsney KM, Barker RA. Pathological mechanisms and clinical aspects of GBA1 mutation-associated Parkinson’s Disease. In: Stoker TB, Greenland JC, editors. Park Dis Pathog Clin Asp [Internet]. Brisbane (AU): Codon Publications; 2018 [cited 2023 Feb 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK536716/
Alaei MR, Tabrizi A, Jafari N, Mozafari H. Gaucher Disease: new expanded classification emphasizing neurological features. Iran J Child Neurol. 2019;13:7–24.
Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, et al. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008;70:2277–83.
doi: 10.1212/01.wnl.0000304039.11891.29
Blumenreich S, Jenkins BJ, Barav OB, Milenkovic I, Futerman AH. The Lysosome and Nonmotor Symptoms: linking Parkinson’s Disease and lysosomal storage disorders. Mov Disord. 2020;35:2150–5.
doi: 10.1002/mds.28232
Pitcairn C, Wani WY, Mazzulli JR. Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson’s disease. Neurobiol Dis. 2019;122:72–82.
doi: 10.1016/j.nbd.2018.03.008
Osellame LD, Rahim AA, Hargreaves IP, Gegg ME, Richard-Londt A, Brandner S, et al. Mitochondria and quality control defects in a mouse model of Gaucher Disease—Links to Parkinson’s Disease. Cell Metab. 2013;17:941–53.
doi: 10.1016/j.cmet.2013.04.014
Rocha EM, Smith GA, Park E, Cao H, Graham A-R, Brown E, et al. Sustained systemic glucocerebrosidase inhibition induces brain α-synuclein aggregation, microglia and complement C1q activation in mice. Antioxid Redox Signal. 2015;23:550–64.
doi: 10.1089/ars.2015.6307
Awad O, Sarkar C, Panicker LM, Miller D, Zeng X, Sgambato JA, et al. Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum Mol Genet. 2015;24:5775–88.
doi: 10.1093/hmg/ddv297
Schöndorf DC, Aureli M, McAllister FE, Hindley CJ, Mayer F, Schmid B, et al. iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun. 2014;5:4028.
doi: 10.1038/ncomms5028
Mazzulli JR, Xu Y-H, Sun Y, Knight AL, McLean PJ, Caldwell GA, et al. Gaucher’s Disease Glucocerebrosidase and <alpha>-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011;146:37–52.
doi: 10.1016/j.cell.2011.06.001
Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov Disord. 2011;26:1049–55.
doi: 10.1002/mds.23732
Soria FN, Engeln M, Martinez-Vicente M, Glangetas C, López-González MJ, Dovero S, et al. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Hum Mol Genet. 2017;26:2603–15.
doi: 10.1093/hmg/ddx120
Conradi NG, Sourander P, Nilsson O, Svennerholm L, Erikson A. Neuropathology of the Norrbottnian type of Gaucher disease. Acta Neuropathol (Berl). 1984;65:99–109.
doi: 10.1007/BF00690463
Sanyal A, Novis HS, Gasser E, Lin S, LaVoie MJ. LRRK2 kinase inhibition rescues deficits in lysosome function due to heterozygous GBA1 expression in human iPSC-derived neurons. Front Neurosci. 2020;14:442.
doi: 10.3389/fnins.2020.00442
Aflaki E, Stubblefield BK, McGlinchey RP, McMahon B, Ory DS, Sidransky E. A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson’s disease. Neurobiol Dis. 2020;134: 104647.
doi: 10.1016/j.nbd.2019.104647
Brunialti E, Villa A, Mekhaeil M, Mornata F, Vegeto E, Maggi A, et al. Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons. J Neuroinflammation. 2021;18:220.
doi: 10.1186/s12974-021-02272-2
Boddupalli CS, Nair S, Belinsky G, Gans J, Teeple E, Nguyen T-H, et al. Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. Zaidi M, editor eLife. 2022;11:e79830.
Wang L, Lin G, Zuo Z, Li Y, Byeon SK, Pandey A, et al. Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. Sci Adv. 8:eabn3326.
Kuhn S, Gritti L, Crooks D, Dombrowski Y. Oligodendrocytes in development, myelin generation and beyond. Cells. 2019;8:1424.
doi: 10.3390/cells8111424
Meschkat M, Steyer AM, Weil M-T, Kusch K, Jahn O, Piepkorn L, et al. White matter integrity in mice requires continuous myelin synthesis at the inner tongue. Nat Commun. 2022;13:1163.
doi: 10.1038/s41467-022-28720-y
Edgar JM, McGowan E, Chapple KJ, Möbius W, Lemgruber L, Insall RH, et al. Río-Hortega’s drawings revisited with fluorescent protein defines a cytoplasm-filled channel system of CNS myelin. J Anat. 2021;239:1241–55.
doi: 10.1111/joa.13577
Kang H, Zhang M, Ouyang M, Guo R, Yu Q, Peng Q, et al. Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging. Eur J Radiol. 2018;102:22–9.
doi: 10.1016/j.ejrad.2018.02.014
Davies EH, Seunarine KK, Banks T, Clark CA, Vellodi A. Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging. J Inherit Metab Dis. 2011;34:549–53.
doi: 10.1007/s10545-011-9288-6
Aronson SM, Volk BW. Cerebral Sphingolipidoses: a symposium on Tay-Sachs’ Disease and allied disorders. Elsevier; 2013. p. 1–474. ISBN: 9781483221519.
Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nat Rev Neurol. 2011;7:229–36.
doi: 10.1038/nrneurol.2011.21
Enquist IB, Nilsson E, Ooka A, Månsson J-E, Olsson K, Ehinger M, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A. 2006;103:13819–24.
doi: 10.1073/pnas.0606016103
Lappe-Siefke C, Goebbels S, Gravel M, Nicksch E, Lee J, Braun PE, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet. 2003;33:366–74.
doi: 10.1038/ng1095
Chen P, Cescon M, Megighian A, Ronaldo P. Collagen VI regulates peripheral nerve myelination and function. FASEB J. 2014;28:1145–56.
doi: 10.1096/fj.13-239533
Jung M, Krämer E, Grzenkowski M, Tang K, Blakemore W, Aguzzi A, et al. Lines of murine oligodendroglial precursor cells immortalized by an activated neu tyrosine kinase show distinct degrees of interaction with axons in vitro and in vivo. Eur J Neurosci. 1995;7:1245–65.
doi: 10.1111/j.1460-9568.1995.tb01115.x
Trotter J, Bitter-Suermann D, Schachner M. Differentiation-regulated loss of the polysialylated embryonic form and expression of the different polypeptides of the neural cell adhesion molecule by cultured oligodendrocytes and myelin. J Neurosci Res. 1989;22:369–83.
doi: 10.1002/jnr.490220402
Zoupi L, Savvaki M, Kalemaki K, Kalafatakis I, Sidiropoulou K, Karagogeos D. The function of contactin-2/TAG-1 in oligodendrocytes in health and demyelinating pathology. Glia. 2018;66:576–91.
doi: 10.1002/glia.23266
Sasaki A, Arawaka S, Sato H, Kato T. Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces. Sci Rep. 2015;5:14211.
doi: 10.1038/srep14211
Thetiot M, Freeman SA, Desmazières A. Immunohistochemical analysis of myelin structures. In: Woodhoo A, editor. Myelin Methods Protoc. New York, NY: Springer; 2018. p. 15–23.
doi: 10.1007/978-1-4939-7862-5_2
He D, Marie C, Zhao C, Kim B, Wang J, Deng Y, et al. Chd7 Cooperates with Sox10 and Regulates the Onset of CNS Myelination and Remyelination. Nat Neurosci. 2016;19:678–89.
doi: 10.1038/nn.4258
de Faria O, Dhaunchak AS, Kamen Y, Roth AD, Kuhlmann T, Colman DR, et al. TMEM10 promotes oligodendrocyte differentiation and is expressed by oligodendrocytes in human remyelinating multiple sclerosis plaques. Sci Rep. 2019;9:3606.
doi: 10.1038/s41598-019-40342-x
Prolo LM, Vogel H, Reimer RJ. The lysosomal sialic acid transporter sialin is required for normal CNS myelination. J Neurosci. 2009;29:15355–65.
doi: 10.1523/JNEUROSCI.3005-09.2009
García-Mateo N, Pascua-Maestro R, Pérez-Castellanos A, Lillo C, Sanchez D, Ganfornina MD. Myelin extracellular leaflet compaction requires apolipoprotein D membrane management to optimize lysosomal-dependent recycling and glycocalyx removal. Glia. 2018;66:670–87.
doi: 10.1002/glia.23274
Magalhaes J, Gegg ME, Migdalska-Richards A, Doherty MK, Whitfield PD, Schapira AHV. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet. 2016;25:3432–45.
doi: 10.1093/hmg/ddw185
Stojkovska I, Krainc D, Mazzulli JR. Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s Disease. Cell Tissue Res. 2018;373:51–60.
doi: 10.1007/s00441-017-2704-y
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-Sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014;34:11929–47.
doi: 10.1523/JNEUROSCI.1860-14.2014
Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, et al. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia. 2014;62:964–70.
doi: 10.1002/glia.22653
Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007;92:336–45.
doi: 10.1016/j.ymgme.2007.08.001
García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, et al. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson’s disease. Mov Disord. 2017;32:1409–22.
doi: 10.1002/mds.27119
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron. 2016;91:56–66.
doi: 10.1016/j.neuron.2016.05.018
Jäkel S, Dimou L. Glial cells and their function in the adult brain: a journey through the history of their ablation. Front Cell Neurosci. 2017;11:24.
doi: 10.3389/fncel.2017.00024
Montero-Odasso M, Pieruccini-Faria F, Bartha R, Black SE, Finger E, Freedman M, et al. Motor phenotype in neurodegenerative disorders: gait and balance platform study design protocol for the ontario neurodegenerative research initiative (ONDRI). J Alzheimer Dis. 2017;59:707–21.
McNeill A, Duran R, Proukakis C, Bras J, Hughes D, Mehta A, et al. Hyposmia and cognitive impairment in Gaucher Disease patients and carriers. Mov Disord Off J Mov Disord Soc. 2012;27:526–32.
doi: 10.1002/mds.24945
Gegg ME, Burke D, Heales SJR, Cooper JM, Hardy J, Wood NW, et al. Glucocerebrosidase deficiency in substantia nigra of Parkinson Disease brains. Ann Neurol. 2012;72:455–63.
doi: 10.1002/ana.23614
Navarro-Romero A, Fernandez-Gonzalez I, Riera J, Montpeyo M, Albert-Bayo M, Lopez-Royo T, et al. Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. Npj Park Dis. 2022;8:1–15.
Trajkovic K, Dhaunchak AS, Goncalves JT, Wenzel D, Schneider A, Bunt G, et al. Neuron to glia signaling triggers myelin membrane exocytosis from endosomal storage sites. J Cell Biol. 2006;172:937–48.
doi: 10.1083/jcb.200509022
Winterstein C, Trotter J, Krämer-Albers E-M. Distinct endocytic recycling of myelin proteins promotes oligodendroglial membrane remodeling. J Cell Sci. 2008;121:834–42.
doi: 10.1242/jcs.022731
Bankston AN, Forston MD, Howard RM, Andres KR, Smith AE, Ohri SS, et al. Autophagy is essential for oligodendrocyte differentiation, survival, and proper myelination. Glia. 2019;67:1745–59.
doi: 10.1002/glia.23646
Folkerth RD. Abnormalities of developing white matter in lysosomal storage diseases. J Neuropathol Exp Neurol. 1999;58:887–902.
doi: 10.1097/00005072-199909000-00001
Ferreira CR, Gahl WA. Lysosomal storage diseases. Transl Sci Rare Dis. 2017;2:1.
Festa LK, Clyde AE, Long CC, Roth LM, Grinspan JB, Jordan-Sciutto KL. Antiretroviral treatment reveals a novel role for lysosomes in oligodendrocyte maturation. J Neurochem. 2023;165:722–40.
doi: 10.1111/jnc.15773
Blanchard JW, Akay LA, Davila-Velderrain J, von Maydell D, Mathys H, Davidson SM, et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature. 2022;611:769–79.
doi: 10.1038/s41586-022-05439-w
Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, et al. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. stem cell Rep. 2015;5:174.
doi: 10.1016/j.stemcr.2015.07.002
May VEL, Ettle B, Poehler A-M, Nuber S, Ubhi K, Rockenstein E, et al. α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy. Neurobiol Aging. 2014;35:2357–68.
doi: 10.1016/j.neurobiolaging.2014.02.028
Kaji S, Maki T, Kinoshita H, Uemura N, Ayaki T, Kawamoto Y, et al. Pathological endogenous α-synuclein accumulation in oligodendrocyte precursor cells potentially induces inclusions in multiple system atrophy. Stem Cell Rep. 2018;10:356–65.
doi: 10.1016/j.stemcr.2017.12.001
Lee H-J, Khoshaghideh F, Patel S, Lee S-J. Clearance of α-Synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004;24:1888–96.
doi: 10.1523/JNEUROSCI.3809-03.2004
Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.
doi: 10.1038/s41419-023-05672-9
Ettle B, Reiprich S, Deusser J, Schlachetzki JCM, Xiang W, Prots I, et al. Intracellular alpha-synuclein affects early maturation of primary oligodendrocyte progenitor cells. Mol Cell Neurosci. 2014;0:68–78.
doi: 10.1016/j.mcn.2014.06.012
Agosta F, Kostic VS, Davidovic K, Kresojević N, Sarro L, Svetel M, et al. White matter abnormalities in Parkinson’s disease patients with glucocerebrosidase gene mutations. Mov Disord. 2013;28:772–8.
doi: 10.1002/mds.25397
Lee SH, Kim SS, Tae WS, Lee SY, Choi JW, Koh SB, et al. Regional volume analysis of the Parkinson Disease brain in early disease stage: gray matter, white matter, striatum, and thalamus. AJNR Am J Neuroradiol. 2011;32:682–7.
doi: 10.3174/ajnr.A2372
Hattori T, Orimo S, Aoki S, Ito K, Abe O, Amano A, et al. Cognitive status correlates with white matter alteration in Parkinson’s disease. Hum Brain Mapp. 2011;33:727–39.
doi: 10.1002/hbm.21245
Duncan GW, Firbank MJ, Yarnall AJ, Khoo TK, Brooks DJ, Barker RA, et al. Gray and white matter imaging: a biomarker for cognitive impairment in early Parkinson’s disease? Mov Disord. 2016;31:103–10.
doi: 10.1002/mds.26312
Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science. 1998;280:1610–3.
doi: 10.1126/science.280.5369.1610
Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485:517–21.
doi: 10.1038/nature11007
Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487:443–8.
doi: 10.1038/nature11314
Fuller M, Futerman AH. The brain lipidome in neurodegenerative lysosomal storage disorders. Biochem Biophys Res Commun. 2018;504:623–8.
doi: 10.1016/j.bbrc.2018.03.042
Leyns CEG, Prigent A, Beezhold B, Yao L, Hatcher NG, Tao P, et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson’s disease. Npj Park Dis. 2023;9:1–14.
Mahoney-Crane CL, Viswanathan M, Russell D, Curtiss RAC, Freire J, Bobba SS, et al. Neuronopathic GBA1L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions. J Neurosci. 2023;43:501–21.
doi: 10.1523/JNEUROSCI.0680-22.2022
Taguchi YV, Liu J, Ruan J, Pacheco J, Zhang X, Abbasi J, et al. Glucosylsphingosine promotes α-synuclein pathology in mutant GBA-associated Parkinson’s Disease. J Neurosci. 2017;37:9617–31.
doi: 10.1523/JNEUROSCI.1525-17.2017
Deane JE, Graham SC, Kim NN, Stein PE, McNair R, Cachón-González MB, et al. Insights into Krabbe disease from structures of galactocerebrosidase. Proc Natl Acad Sci U S A. 2011;108:15169–73.
doi: 10.1073/pnas.1105639108
Schuchman EH, Desnick RJ. Types A and B Niemann-Pick Disease. Mol Genet Metab. 2017;120:27–33.
doi: 10.1016/j.ymgme.2016.12.008
Jung W, Liu C, Yu Y, Chang Y, Lien W, Chao H, et al. Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation in vivo. EMBO Rep. 2017;18:1150–65.
doi: 10.15252/embr.201643480
Pant DC, Dorboz I, Schluter A, Fourcade S, Launay N, Joya J, et al. Loss of the sphingolipid desaturase DEGS1 causes hypomyelinating leukodystrophy. J Clin Invest. 2019;129:1240–56.
Shimizu T, Schutt CR, Izumi Y, Tomiyasu N, Omahdi Z, Kano K, et al. Direct activation of microglia by β-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease. Immunity. 2023;56:307-319.e8.
doi: 10.1016/j.immuni.2023.01.008
Zunke F, Moise AC, Belur NR, Gelyana E, Stojkovska I, Dzaferbegovic H, et al. Reversible conformational conversion of α-synuclein into toxic assemblies by glucosylceramide. Neuron. 2018;97:92-107.e10.
doi: 10.1016/j.neuron.2017.12.012
Paul A, Jacoby G, Laor Bar-Yosef D, Beck R, Gazit E, Segal D. Glucosylceramide associated with Gaucher Disease forms amyloid-like twisted ribbon fibrils that induce α-synuclein Aggregation. ACS Nano. 2021;15:11854–68.
doi: 10.1021/acsnano.1c02957
Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson’s disease. Nat Commun. 2021;12:1807.
doi: 10.1038/s41467-021-22113-3
Alaamery M, Albesher N, Aljawini N, Alsuwailm M, Massadeh S, Wheeler MA, et al. Role of sphingolipid metabolism in neurodegeneration. J Neurochem. 2021;158:25–35.
doi: 10.1111/jnc.15044
Abbott SK, Li H, Muñoz SS, Knoch B, Batterham M, Murphy KE, et al. Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord. 2014;29:518–26.
doi: 10.1002/mds.25729
Mielke MM, Maetzler W, Haughey NJ, Bandaru VVR, Savica R, Deuschle C, et al. Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson’s Disease and associated with cognitive impairment: a pilot study. PLoS ONE. 2013;8: e73094.
doi: 10.1371/journal.pone.0073094
Pellicano C, Benincasa D, Pisani V, Buttarelli FR, Giovannelli M, Pontieri FE. Prodromal non-motor symptoms of Parkinson’s disease. Neuropsychiatr Dis Treat. 2007;3:145–52.
doi: 10.2147/nedt.2007.3.1.145
Moustafa AA, Chakravarthy S, Phillips JR, Gupta A, Keri S, Polner B, et al. Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev. 2016;68:727–40.
doi: 10.1016/j.neubiorev.2016.07.010
Amende I, Kale A, McCue S, Glazier S, Morgan JP, Hampton TG. Gait dynamics in mouse models of Parkinson’s disease and Huntington’s disease. J Neuroengineering Rehabil. 2005;2:20.
doi: 10.1186/1743-0003-2-20
Dai M, Liou B, Swope B, Wang X, Zhang W, Inskeep V, et al. Progression of behavioral and CNS deficits in a viable murine model of chronic neuronopathic Gaucher Disease. PLoS ONE. 2016;11: e0162367.
doi: 10.1371/journal.pone.0162367
Farfel-Becker T, Do J, Tayebi N, Sidransky E. Can GBA1-associated parkinson disease be modeled in the mouse? Trends Neurosci. 2019;42:631–43.
doi: 10.1016/j.tins.2019.05.010
Fernagut PO, Diguet E, Labattu B, Tison F. A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 2002;113:123–30.
doi: 10.1016/S0165-0270(01)00485-X
Lamontagne-Proulx J, Coulombe K, Morissette M, Rieux M, Calon F, Di Paolo T, et al. Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules. 2023;13:977.
doi: 10.3390/biom13060977
Taguchi T, Ikuno M, Hondo M, Parajuli LK, Taguchi K, Ueda J, et al. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson’s disease model. Brain. 2020;143:249–65.
doi: 10.1093/brain/awz380
Prediger RD, Schamne MG, Sampaio TB, Moreira ELG, Rial D. Animal models of olfactory dysfunction in neurodegenerative diseases. Handb Clin Neurol. 2019;164:431–52.
doi: 10.1016/B978-0-444-63855-7.00024-1
Cerri S, Mus L, Blandini F. Parkinson’s Disease in women and men: what’s the difference? J Park Dis. 2019;9:501–15.
Li Q, Jing Y, Lun P, Liu X, Sun P. Association of gender and age at onset with glucocerebrosidase associated Parkinson’s disease: a systematic review and meta-analysis. Neurol Sci. 2021;42:2261–71.
doi: 10.1007/s10072-021-05230-1
Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, et al. Clinical and dopamine transporter imaging characteristics of leucine- rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson’s Disease participants in the Parkinson’s Progression Markers Initiative: a cross-sectional study. Mov Disord Off J Mov Disord Soc. 2020;35:833–44.
doi: 10.1002/mds.27989
Brunialti E, Villa A, Toffoli M, Lucas Del Pozo S, Rizzi N, Meda C, et al. sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-Linked Parkinson’s Disease. Cells. 2023;12:343.
doi: 10.3390/cells12030343